Seasonal influenza vaccine dose distribution in 157 countries (2004-2011).

Globally there are an estimated 3-5 million cases of severe influenza illness every year, resulting in 250,000-500,000 deaths. At the World Health Assembly in 2003, World Health Organization (WHO) resolved to increase influenza vaccine coverage rates (VCR) for high-risk groups, particularly focusing on at least 75% of the elderly by 2010. But systematic worldwide data have not been available to assist public health authorities to monitor vaccine uptake and review progress toward vaccination coverage targets. In 2008, the International Federation of Pharmaceutical Manufacturers and Associations Influenza Vaccine Supply task force (IFPMA IVS) developed a survey methodology to assess global influenza vaccine dose distribution. The current survey results represent 2011 data and demonstrate the evolution of the absolute number distributed between 2004 and 2011 inclusive, and the evolution in the per capita doses distributed in 2008-2011. Global distribution of IFPMA IVS member doses increased approximately 86.9% between 2004 and 2011, but only approximately 12.1% between 2008 and 2011. The WHO's regions in Eastern Mediterranean (EMRO), Southeast Asian (SEARO) and Africa (AFRO) together account for about 47% of the global population, but only 3.7% of all IFPMA IVS doses distributed. While distributed doses have globally increased, they have decreased in EURO and EMRO since 2009. Dose distribution can provide a reasonable proxy of vaccine utilization. Based on the dose distribution, we conclude that seasonal influenza VCR in many countries remains well below the WHA's VCR targets and below the recommendations of the Council of the European Union in EURO. Inter- and intra-regional disparities in dose distribution trends call into question the impact of current vaccine recommendations at achieving coverage targets. Additional policy measures, particularly those that influence patients adherence to vaccination programs, such as reimbursement, healthcare provider knowledge, attitudes, practices, and communications, are required for VCR targets to be met and benefit public health.

[1]  M. Kieny,et al.  Global production capacity of seasonal influenza vaccine in 2011. , 2013, Vaccine.

[2]  N. Cox,et al.  Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009. , 2009 .

[3]  A. Palache.  Seasonal influenza vaccine provision in 157 countries (2004-2009) and the potential influence of national public health policies. , 2011, Vaccine.

[4]  F. Carrat,et al.  Trends in influenza vaccination behaviours--results from the CoPanFlu cohort, France, 2006 to 2011. , 2013, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[5]  Stella M. Yu.  Healthy People 2010 , 1998, Maternal and Child Health Journal.

[6]  S. Himanen,et al.  AS03 Adjuvanted AH1N1 Vaccine Associated with an Abrupt Increase in the Incidence of Childhood Narcolepsy in Finland , 2012, PloS one.

[7]  A. Palache,et al.  Annual public health and economic benefits of seasonal influenza vaccination: a European estimate , 2014, BMC Public Health.

[8]  K. Nichol,et al.  Cost-effectiveness of a recommendation of universal mass vaccination for seasonal influenza in the United States. , 2011, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[9]  T. Carter,et al.  Implications for Policy , 1988 .

[10]  N. Cox,et al.  Prevention and Control of Influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). , 2006, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.

[11]  M. Jit,et al.  Health and economic impact of the seasonal influenza vaccination programme in England. , 2012, Vaccine.

[12]  P. Peretti-Watel,et al.  Dramatic change in public attitudes towards vaccination during the 2009 influenza A(H1N1) pandemic in France. , 2013, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[13]  N. Andrews,et al.  Risk of narcolepsy in children and young people receiving AS03 adjuvanted pandemic A/H1N1 2009 influenza vaccine: retrospective analysis , 2013, BMJ : British Medical Journal.